Updates: Office of Infectious Disease and HIV/AIDS Policy
June 18, 2021

Division of Vaccines
Office of Infectious Disease and HIV/AIDS Policy
Office of the Assistant Secretary for Health
National Vaccine Advisory Committee

- Met on June 16–17, 2021
- Updates from Vaccine Confidence and Immunization Equity Subcommittees; vote on immunization equity report
- Catch up vaccinations for adults and adolescents
- Update on COVID-19 vaccines
  - Vaccine safety updates
  - Implications for variants
  - Authorizations for use
- Next meeting TBD
National Vaccine Plan 2021–2025 Implementation

• Vaccines National Strategic Plan 2021–2025 released on January 19

• 5 overarching goals
  ▪ Vaccine innovation
  ▪ Vaccine safety
  ▪ Vaccine confidence
  ▪ Access to vaccines
  ▪ Global collaboration

• Implementation plan to be developed in collaboration with federal partners
Vaccine Safety Report

• AHRQ released updated systematic review of adverse events associated with routinely recommended vaccines on May 25
• Literature review through November 9, 2020; plus trial registries, other materials
• Reviewed observed rates, relative risks for key adverse events; assessed strength of evidence
• Included new vaccines since 2014 (e.g., recombinant and adjuvanted influenza vaccines, recombinant zoster vaccine, hepatitis B vaccine with novel adjuvant)
• Does not include COVID-19 vaccines
Vaccine Safety Report (2)

• Outcomes: adverse events identified in participants (for pregnant women, in fetuses and infants); presence or absence of harms, toxicities, transient side effects, adverse health outcomes

• Key adverse events: cardiovascular events, autoimmune disease, Guillain-Barre syndrome, seizures, anaphylaxis, idiopathic thrombocytopenic purpura, reproductive system events, death

• Timing of outcomes: short = 30–42 days after vaccination, long = >42 days after vaccination
Vaccine Safety Report (3)

• Screened 56,608 citations, reviewed 338 studies in 518 publications

• No new evidence of increased risk for key adverse events for adults, children, pregnant people

• Safety signals from prior reports (e.g., anaphylaxis, febrile seizures) remain unchanged for children and adults

• No evidence of increased adverse events in pregnant people

• Insufficient data for some rare potential adverse events

• https://effectivehealthcare.ahrq.gov/products/safety-vaccines/research